Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection

Publikation

Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection

Wissenschaftlicher Artikel/Review - 12.01.2012

Clifford G M, Schöni-Affolter F, Keiser O, Calmy A, Cavassini M, Bernasconi E, Battegay M, Schmid Patrick, Fehr J, Wandeler G, Jundt G, Ess S, Levi F, Korol D, Bouchardy C, Egger M, Franceschi S, Lise M, Swiss HIV Cohort Study

Zitation

Clifford G, Schöni-Affolter F, Keiser O, Calmy A, Cavassini M, Bernasconi E, Battegay M, Schmid P, Fehr J, Wandeler G, Jundt G, Ess S, Levi F, Korol D, Bouchardy C, Egger M, Franceschi S, Lise M, Swiss HIV Cohort Study. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 2012; 106:447-52.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Br J Cancer 2012; 106

Veröffentlichungsdatum

12.01.2012

eISSN (Online)

1532-1827

Seiten

447-52

Kurzbeschreibung/Zielsetzung

BACKGROUND
Immunodeficiency and AIDS-related pulmonary infections have been suggested as independent causes of lung cancer among HIV-infected persons, in addition to smoking.

METHODS
A total of 68 lung cancers were identified in the Swiss HIV Cohort Study (SHCS) or through linkage with Swiss Cancer Registries (1985-2010), and were individually matched to 337 controls by centre, gender, HIV-transmission category, age and calendar period. Odds ratios (ORs) were estimated by conditional logistic regression.

RESULTS
Overall, 96.2% of lung cancers and 72.9% of controls were ever smokers, confirming the high prevalence of smoking and its strong association with lung cancer (OR for current vs never=14.4, 95% confidence interval (95% CI): 3.36-62.1). No significant associations were observed between CD4+ cell count and lung cancer, neither when measured within 1 year (OR for <200 vs ≥500=1.21, 95% CI: 0.49-2.96) nor further back in time, before lung cancer diagnosis. Combined antiretroviral therapy was not significantly associated with lung cancer (OR for ever vs never=0.67, 95% CI: 0.29-1.52), and nor was a history of AIDS with (OR=0.49, 95% CI: 0.19-1.28) or without (OR=0.53, 95% CI: 0.24-1.18) pulmonary involvement.

CONCLUSION
Lung cancer in the SHCS does not seem to be clearly associated with immunodeficiency or AIDS-related pulmonary disease, but seems to be attributable to heavy smoking.